Compare ANIP & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | PENN |
|---|---|---|
| Founded | 2001 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1999 | 1996 |
| Metric | ANIP | PENN |
|---|---|---|
| Price | $72.10 | $14.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $107.33 | $20.14 |
| AVG Volume (30 Days) | 336.7K | ★ 4.5M |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 419.23 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | $206,547,000.00 | ★ $6,362,900,000.00 |
| Revenue This Year | $19.88 | $6.02 |
| Revenue Next Year | $15.77 | $4.31 |
| P/E Ratio | $21.19 | ★ N/A |
| Revenue Growth | ★ 2.47 | N/A |
| 52 Week Low | $56.71 | $11.65 |
| 52 Week High | $99.50 | $20.61 |
| Indicator | ANIP | PENN |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 49.37 |
| Support Level | $62.89 | $13.87 |
| Resistance Level | $85.12 | $15.36 |
| Average True Range (ATR) | 2.64 | 0.82 |
| MACD | -0.27 | -0.02 |
| Stochastic Oscillator | 25.10 | 50.36 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.